-
1
-
-
80052763462
-
Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi55-8.
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 6
-
-
Eichenauer, D.A.1
Engert, A.2
Dreyling, M.3
-
2
-
-
34548186696
-
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial
-
Aug 10
-
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502.
-
(2007)
J Clin Oncol
, vol.25
, Issue.23
, pp. 3495-3502
-
-
Engert, A.1
Franklin, J.2
Eich, H.T.3
Brillant, C.4
Sehlen, S.5
Cartoni, C.6
-
3
-
-
35848959692
-
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
-
Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916-27.
-
(2007)
N Engl J Med
, vol.357
, Issue.19
, pp. 1916-1927
-
-
Ferme, C.1
Eghbali, H.2
Meerwaldt, J.H.3
Rieux, C.4
Bosq, J.5
Berger, F.6
-
4
-
-
77956646155
-
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
-
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-52.
-
(2010)
N Engl J Med
, vol.363
, Issue.7
, pp. 640-652
-
-
Engert, A.1
Plutschow, A.2
Eich, H.T.3
Lohri, A.4
Dorken, B.5
Borchmann, P.6
-
5
-
-
78149436503
-
Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: Results of the second interim analysis of the GHSG HD13 trial
-
Borchmann P, Diehl V, Goergen H, Lohri A, Zijlstra J, Topp M, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica. 2010;95, Suppl. 2(473):A1146.
-
(2010)
Haematologica
, vol.95 SUPPL. 2
, Issue.473
-
-
Borchmann, P.1
Diehl, V.2
Goergen, H.3
Lohri, A.4
Zijlstra, J.5
Topp, M.6
-
6
-
-
77957945999
-
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial
-
Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-206.
-
(2010)
J Clin Oncol
, vol.28
, Issue.27
, pp. 4199-4206
-
-
Eich, H.T.1
Diehl, V.2
Gorgen, H.3
Pabst, T.4
Markova, J.5
Debus, J.6
-
7
-
-
24944460608
-
First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
-
Noordijk EM, Thomas J, Ferme C, van't Veer MB, Brice P, Divine M, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). ASCO Meeting Abstracts. 2005;23(16 Suppl):6505.
-
(2005)
ASCO Meeting Abstracts
, vol.23
, Issue.16 SUPPL.
, pp. 6505
-
-
Noordijk, E.M.1
Thomas, J.2
Ferme, C.3
Van'T Veer, M.B.4
Brice, P.5
Divine, M.6
-
8
-
-
84860626866
-
Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German hodgkin study group HD14 trial
-
von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol. 2012;30(9):907-13.
-
(2012)
J Clin Oncol
, vol.30
, Issue.9
, pp. 907-913
-
-
Von Tresckow, B.1
Plutschow, A.2
Fuchs, M.3
Klimm, B.4
Markova, J.5
Lohri, A.6
-
9
-
-
0032422646
-
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial
-
German Hodgkin's Lymphoma Study Group
-
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16(12):3810-21.
-
(1998)
J Clin Oncol
, vol.16
, Issue.12
, pp. 3810-3821
-
-
Diehl, V.1
Franklin, J.2
Hasenclever, D.3
Tesch, H.4
Pfreundschuh, M.5
Lathan, B.6
-
10
-
-
84863011979
-
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma
-
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
-
(2012)
N Engl J Med
, vol.366
, Issue.5
, pp. 399-408
-
-
Meyer, R.M.1
Gospodarowicz, M.K.2
Connors, J.M.3
Pearcey, R.G.4
Wells, W.A.5
Winter, J.N.6
-
11
-
-
0026439199
-
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
-
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-84.
-
(1992)
N Engl J Med
, vol.327
, Issue.21
, pp. 1478-1484
-
-
Canellos, G.P.1
Anderson, J.R.2
Propert, K.J.3
Nissen, N.4
Cooper, M.R.5
Henderson, E.S.6
-
12
-
-
0037007678
-
Long-term follow-up of Hodgkin's disease trial
-
Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002;346(18):1417-8.
-
(2002)
N Engl J Med
, vol.346
, Issue.18
, pp. 1417-1418
-
-
Canellos, G.P.1
Niedzwiecki, D.2
-
13
-
-
71849109593
-
Long-term follow-up of survival in Hodgkin's lymphoma
-
Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009;361(24):2390-1.
-
(2009)
N Engl J Med
, vol.361
, Issue.24
, pp. 2390-2391
-
-
Canellos, G.P.1
Niedzwiecki, D.2
Johnson, J.L.3
-
14
-
-
0037567428
-
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
-
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-95.
-
(2003)
N Engl J Med
, vol.348
, Issue.24
, pp. 2386-2395
-
-
Diehl, V.1
Franklin, J.2
Pfreundschuh, M.3
Lathan, B.4
Paulus, U.5
Hasenclever, D.6
-
15
-
-
71049118685
-
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
-
Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-54.
-
(2009)
J Clin Oncol
, vol.27
, Issue.27
, pp. 4548-4554
-
-
Engert, A.1
Diehl, V.2
Franklin, J.3
Lohri, A.4
Dorken, B.5
Ludwig, W.D.6
-
16
-
-
84860833364
-
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial
-
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-9.
-
(2012)
Lancet
, vol.379
, Issue.9828
, pp. 1791-1799
-
-
Engert, A.1
Haverkamp, H.2
Kobe, C.3
Markova, J.4
Renner, C.5
Ho, A.6
-
17
-
-
21344435055
-
Elevated serum levels of CC thymus and activation- related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor
-
Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, et al. Elevated serum levels of CC thymus and activation- related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005;65(13):5516-9.
-
(2005)
Cancer Res
, vol.65
, Issue.13
, pp. 5516-5519
-
-
Weihrauch, M.R.1
Manzke, O.2
Beyer, M.3
Haverkamp, H.4
Diehl, V.5
Bohlen, H.6
-
18
-
-
84857749434
-
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma
-
Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruim J, Vos H, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012;97(3):410-5.
-
(2012)
Haematologica
, vol.97
, Issue.3
, pp. 410-415
-
-
Plattel, W.J.1
Van Den Berg, A.2
Visser, L.3
Van Der Graaf, A.M.4
Pruim, J.5
Vos, H.6
-
19
-
-
77949345555
-
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma
-
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-85.
-
(2010)
N Engl J Med
, vol.362
, Issue.10
, pp. 875-885
-
-
Steidl, C.1
Lee, T.2
Shah, S.P.3
Farinha, P.4
Han, G.5
Nayar, T.6
-
20
-
-
84868116570
-
Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial
-
Sep 4
-
Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012 Sep 4.
-
(2012)
Blood
-
-
Tan, K.L.1
Scott, D.W.2
Hong, F.3
Kahl, B.S.4
Fisher, R.I.5
Bartlett, N.L.6
-
21
-
-
0027404777
-
Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
-
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852): 1051-4.
-
(1993)
Lancet
, vol.341
, Issue.8852
, pp. 1051-1054
-
-
Linch, D.C.1
Winfield, D.2
Goldstone, A.H.3
Moir, D.4
Hancock, B.5
McMillan, A.6
-
22
-
-
0037097044
-
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial
-
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-71.
-
(2002)
Lancet
, vol.359
, Issue.9323
, pp. 2065-2071
-
-
Schmitz, N.1
Pfistner, B.2
Sextro, M.3
Sieber, M.4
Carella, A.M.5
Haenel, M.6
-
23
-
-
79951890275
-
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
-
Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28(34): 5074-80.
-
(2010)
J Clin Oncol
, vol.28
, Issue.34
, pp. 5074-5080
-
-
Josting, A.1
Muller, H.2
Borchmann, P.3
Baars, J.W.4
Metzner, B.5
Dohner, H.6
-
24
-
-
33846925670
-
Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma
-
Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92(1):35-41.
-
(2007)
Haematologica
, vol.92
, Issue.1
, pp. 35-41
-
-
Santoro, A.1
Magagnoli, M.2
Spina, M.3
Pinotti, G.4
Siracusano, L.5
Michieli, M.6
-
25
-
-
0035253827
-
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
-
Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-23.
-
(2001)
Blood
, vol.97
, Issue.3
, pp. 616-623
-
-
Moskowitz, C.H.1
Nimer, S.D.2
Zelenetz, A.D.3
Trippett, T.4
Hedrick, E.E.5
Filippa, D.A.6
-
26
-
-
24644460669
-
Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group
-
Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Duhmke E, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052-60.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 5052-5060
-
-
Engert, A.1
Ballova, V.2
Haverkamp, H.3
Pfistner, B.4
Josting, A.5
Duhmke, E.6
-
27
-
-
78951482387
-
Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: Analysis of two randomized prospective multicenter trials
-
German Hodgkin Study Group (HD10 and HD11) November 19
-
Boll B, Gorgen H, Fuchs M, von Tresckow B, Engert A, Borchmann P. Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: analysis of two randomized prospective multicenter trials of the German Hodgkin Study Group (HD10 and HD11). ASH annual meeting abstracts. 2010 November 19, 2010;116(21):418.
-
(2010)
ASH Annual Meeting Abstracts 2010
, vol.116
, Issue.21
, pp. 418
-
-
Boll, B.1
Gorgen, H.2
Fuchs, M.3
Von Tresckow, B.4
Engert, A.5
Borchmann, P.6
-
28
-
-
83455220148
-
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
-
Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292-8.
-
(2011)
Blood
, vol.118
, Issue.24
, pp. 6292-6298
-
-
Boll, B.1
Bredenfeld, H.2
Gorgen, H.3
Halbsguth, T.4
Eich, H.T.5
Soekler, M.6
-
29
-
-
84862734110
-
Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: The SHIELD study
-
Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-15.
-
(2012)
Blood
, vol.119
, Issue.25
, pp. 6005-6015
-
-
Proctor, S.J.1
Wilkinson, J.2
Jones, G.3
Watson, G.C.4
Lucraft, H.H.5
Mainou-Fowler, T.6
-
30
-
-
0033932803
-
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study
-
Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615-9.
-
(2000)
J Clin Oncol
, vol.18
, Issue.13
, pp. 2615-2619
-
-
Santoro, A.1
Bredenfeld, H.2
Devizzi, L.3
Tesch, H.4
Bonfante, V.5
Viviani, S.6
-
31
-
-
39049195371
-
Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma
-
Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006;2006:266-72.
-
(2006)
Hematology Am Soc Hematol Educ Program
, vol.2006
, pp. 266-272
-
-
Nogova, L.1
Rudiger, T.2
Engert, A.3
-
32
-
-
38649125204
-
Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group
-
Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26(3):434-9.
-
(2008)
J Clin Oncol
, vol.26
, Issue.3
, pp. 434-439
-
-
Nogova, L.1
Reineke, T.2
Brillant, C.3
Sieniawski, M.4
Rudiger, T.5
Josting, A.6
-
33
-
-
27144479926
-
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)
-
Nogova L, Reineke T, Eich HT, Josting A, Muller-Hermelink HK, Wingbermuhle K, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16(10):1683-7.
-
(2005)
Ann Oncol
, vol.16
, Issue.10
, pp. 1683-1687
-
-
Nogova, L.1
Reineke, T.2
Eich, H.T.3
Josting, A.4
Muller-Hermelink, H.K.5
Wingbermuhle, K.6
-
34
-
-
84861813756
-
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
-
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5):589-97.
-
(2012)
J Natl Compr Canc Netw
, vol.10
, Issue.5
, pp. 589-597
-
-
Hoppe, R.T.1
Advani, R.H.2
Ai, W.Z.3
Ambinder, R.F.4
Aoun, P.5
Bello, C.M.6
-
35
-
-
73949125030
-
Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up
-
Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28(1):136-41.
-
(2010)
J Clin Oncol
, vol.28
, Issue.1
, pp. 136-141
-
-
Chen, R.C.1
Chin, M.S.2
Ng, A.K.3
Feng, Y.4
Neuberg, D.5
Silver, B.6
-
36
-
-
80054835220
-
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
-
Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118(16):4363-5.
-
(2011)
Blood
, vol.118
, Issue.16
, pp. 4363-4365
-
-
Eichenauer, D.A.1
Fuchs, M.2
Pluetschow, A.3
Klimm, B.4
Halbsguth, T.5
Boll, B.6
-
37
-
-
77957133359
-
Lymphocyte-predominant Hodgkin lymphoma- clinical features and treatment outcomes from a 30-year experience
-
Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma- clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010;21(10):2061-8.
-
(2010)
Ann Oncol
, vol.21
, Issue.10
, pp. 2061-2068
-
-
Jackson, C.1
Sirohi, B.2
Cunningham, D.3
Horwich, A.4
Thomas, K.5
Wotherspoon, A.6
-
38
-
-
38049162295
-
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
-
Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109-11.
-
(2008)
Blood
, vol.111
, Issue.1
, pp. 109-111
-
-
Schulz, H.1
Rehwald, U.2
Morschhauser, F.3
Elter, T.4
Driessen, C.5
Rudiger, T.6
-
39
-
-
59449100987
-
Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort
-
(June):abstract 118
-
Horning S, Fanale M, De Vos S, Borchmann P, Illidge T, Engert A, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008;19(Suppl 4) (June):abstract 118.
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL. 4
-
-
Horning, S.1
Fanale, M.2
De Vos, S.3
Borchmann, P.4
Illidge, T.5
Engert, A.6
-
40
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): 1812-21.
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1812-1821
-
-
Younes, A.1
Bartlett, N.L.2
Leonard, J.P.3
Kennedy, D.A.4
Lynch, C.M.5
Sievers, E.L.6
-
41
-
-
84863676500
-
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
-
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9.
-
(2012)
J Clin Oncol
, vol.30
, Issue.18
, pp. 2183-2189
-
-
Younes, A.1
Gopal, A.K.2
Smith, S.E.3
Ansell, S.M.4
Rosenblatt, J.D.5
Savage, K.J.6
-
42
-
-
84865189087
-
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies
-
German Hodgkin Study Group experience
-
Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jager U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-2.
-
(2012)
Blood
, vol.120
, Issue.7
, pp. 1470-1472
-
-
Rothe, A.1
Sasse, S.2
Goergen, H.3
Eichenauer, D.A.4
Lohri, A.5
Jager, U.6
-
43
-
-
84863522501
-
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
-
Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26): 6379-81.
-
(2012)
Blood
, vol.119
, Issue.26
, pp. 6379-6381
-
-
Chen, R.1
Palmer, J.M.2
Thomas, S.H.3
Tsai, N.C.4
Farol, L.5
Nademanee, A.6
-
44
-
-
84864132475
-
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
-
Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-8.
-
(2012)
Blood
, vol.120
, Issue.3
, pp. 560-568
-
-
Gopal, A.K.1
Ramchandren, R.2
O'Connor, O.A.3
Berryman, R.B.4
Advani, R.H.5
Chen, R.6
-
45
-
-
84865235209
-
Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase i studies
-
Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist. 2012;17(8):1073-80.
-
(2012)
Oncologist
, vol.17
, Issue.8
, pp. 1073-1080
-
-
Forero-Torres, A.1
Fanale, M.2
Advani, R.3
Bartlett, N.L.4
Rosenblatt, J.D.5
Kennedy, D.A.6
-
46
-
-
74049104854
-
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
-
Boll B, Borchmann P, Topp MS, Hanel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010;148(3):480-2.
-
(2010)
Br J Haematol
, vol.148
, Issue.3
, pp. 480-482
-
-
Boll, B.1
Borchmann, P.2
Topp, M.S.3
Hanel, M.4
Reiners, K.S.5
Engert, A.6
-
47
-
-
81055123994
-
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
-
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-25.
-
(2011)
Blood
, vol.118
, Issue.19
, pp. 5119-5125
-
-
Fehniger, T.A.1
Larson, S.2
Trinkaus, K.3
Siegel, M.J.4
Cashen, A.F.5
Blum, K.A.6
-
48
-
-
77951559617
-
A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
-
Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-4.
-
(2010)
Am J Hematol
, vol.85
, Issue.5
, pp. 320-324
-
-
Johnston, P.B.1
Inwards, D.J.2
Colgan, J.P.3
Laplant, B.R.4
Kabat, B.F.5
Habermann, T.M.6
-
49
-
-
84864024420
-
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study
-
Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197-203.
-
(2012)
J Clin Oncol
, vol.30
, Issue.18
, pp. 2197-2203
-
-
Younes, A.1
Sureda, A.2
Ben-Yehuda, D.3
Zinzani, P.L.4
Ong, T.C.5
Prince, H.M.6
|